VFY Expands Partnerships and U.S. Reach as Device Listing Nears Year-End
According to TradingView, VFY reported wider partnerships in blood and cell and gene therapy, with quarter-end cash at AUD 38.3 million.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, VFY reported expanded partnerships across blood and cell and gene therapy.
Management remains on track for a U.S. device listing by year-end, with blood supply for validation the main condition.
Quarter-end cash stood at AUD 38.3 million, which the company expects to fund operations into calendar 2028.
why it matters
For a company of this size, routine updates like this rarely move the stock on their own. The cash runway into 2028 reduces near-term funding pressure, while the timing of the U.S. listing remains the key item for investors to watch.
tags
instruments
sources
- VFY: Partnerships and U.S. market reach accelerated as device listing advances toward year-end — TradingView, 27 October 2026 at 23:46 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗